51-08-1

Basic information

• Product Name: 4-amino-N-(2-piperidinoethyl)benzenecarboxamide
• Synonyms: 4-amino-N-(2-piperidinoethyl)benzenecarboxamide
• CAS NO: 51-08-1
• Molecular Formula: C₁₄H₂₁N₃O
• Molecular Weight: 247.34
• Mol File: 51-08-1.mol
• Article Data: 5

Chemical Properties

• Melting Point: 118-120°
• Appearance: /
• CAS DataBase Reference: 4-amino-N-(2-piperidinoethyl)benzenecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-N-(2-piperidinoethyl)benzenecarboxamide(51-08-1)
• EPA Substance Registry System: 4-amino-N-(2-piperidinoethyl)benzenecarboxamide(51-08-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 51-08-1(Hazardous Substances Data)

Usage

General Description

4-amino-N-(2-piperidinoethyl)benzenecarboxamide, also known as procainamide, is a medication used to treat irregular heartbeats, specifically ventricular arrhythmias. It works by blocking sodium channels in the heart muscle, which helps to stabilize the heart rhythm. Procainamide is a derivative of the amino acid para-aminobenzoic acid, and its chemical structure contains an amino group, a piperidine ring, and a carboxamide group. It is administered orally or intravenously and is metabolized in the liver. Common side effects of procainamide include nausea, dizziness, and low blood pressure. It is important to monitor the blood levels of procainamide to ensure the appropriate dosage and to minimize the risk of toxic effects.

Upstream product

• 27578-60-5 1-(2-aminoethyl)piperidine 
• 66493-39-8 4-(N-tert-butoxycarbonyl)aminobenzoic acid 
• 1664-31-9 4-nitro-N-(2-(piperidin-1-yl)ethyl)benzamide 
• 122-04-3 4-nitro-benzoyl chloride 
• 2038-03-1 4-(2-AMINOETHYL)MORPHOLINE 

Downstream Products

• 1197162-90-5 4-({[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-(2-piperidin-1-ylethyl)benzamide 
• 1197166-08-7 4-{[(4-{4-morpholin-4-yl-6-[(3S)-tetrahydrofuran-3-yloxy]-1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}-N-(2-piperidin-1-ylethyl)benzamide 

Relevant articles and documents

Comparative study of dG affinity vs. DNA methylation modulating properties of side chain derivatives of procainamide: Insight into its DNA hypomethylating effect

Procainamide derivatives have been synthesized to investigate the role of side chains in modulating the DNA methylation level in cancer cells and gain insight into its mechanism of action. The synthesized derivatives comprised of flexible (dimethyl), cons

Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors

The o-carboxylic acid substituted bisanilinopyrimidine 1 was identified as a potent hit (Aurora A IC50 = 6.1 ± 1.0 nM) from in-house screening. Detailed structure-activity relationship (SAR) studies indicated that polar substituents at the para position of the B-ring are critical for potent activity. X-ray crystallography studies revealed that compound 1 is a type I inhibitor that binds the Aurora kinase active site in a DFG-in conformation. Structure-activity guided replacement of the A-ring carboxylic acid with halogens and incorporation of fluorine at the pyrimidine 5-position led to highly potent inhibitors of Aurora A that bind in a DFG-out conformation. B-Ring modifications were undertaken to improve the solubility and cell permeability. Compounds such as 9m with water-solubilizing moieties at the para position of the B-ring inhibited the autophosphorylation of Aurora A in MDA-MB-468 breast cancer cells.

NOVEL CARBOXAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS

Novel compounds of formula (I) which modulate MCH activity are disclosed, in which A is a linker; B is a connecting moiety; Ar1 and Ar2 are aryl or heteroaryl groups; R1 and R2 are hydrogen, halogen atoms, CF3, OCF3/